BC
CMPX icon

Birchview Capital’s Compass Therapeutics CMPX Stock Holding History

Birchview Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Buy
1,675,000
+209,133
+14% +$617K 1.72% 15
2026
Q1 		$7.75M Sell
1,465,867
-127,071
-8% -$733K 4.41% 3
2025
Q4 		$8.55M Buy
1,592,938
+720,000
+82% +$3.32M 5.01% 3
2025
Q3 		$3.06M Buy
+872,938
New +$2.76M 2.31% 11
2025
Q2 		– Sell
-24,000
Closed -$45.6K – 74
2025
Q1 		$45.6K Buy
+24,000
New +$63.8K 0.04% 66

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Birchview Capital's CMPX Position: Q2 2026 in Review

Birchview Capital increased its Compass Therapeutics (CMPX) stake by 14% in Q2 2026, buying an estimated $617K and bringing the position to 1,675,000 shares worth $3.67M. The position accounts for 1.72% of the portfolio, ranked #15.

Birchview Capital first reported a position in CMPX in Q1 2025 and has held it in 5 quarters since. The position peaked at $8.55M in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Birchview Capital held 1,675,000 shares of Compass Therapeutics worth $3.67M as of Q2 2026.
  • Birchview Capital bought 209,133 Compass Therapeutics shares in Q2 2026, an estimated $617K.
  • Compass Therapeutics made up 1.72% of Birchview Capital's portfolio in Q2 2026, its #15 holding.
  • Birchview Capital first reported a position in Compass Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Birchview Capital's Compass Therapeutics position peaked at $8.55M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.